Search
viloxazine (Qelbree)
Indications:
- treatment of attention-deficit hyperactivity disorder (ADHD) in children 6-17 years [1] & adults [2,3]
Contraindications:
- concurrent administration of MAO inhibitor (within 14 days)
- pregnancy
Dosage:
- start 100 mg PO QD
- may increase by 100 mg weekly to maximum of 400 mg PO QD
Capsules: 100, 120 & 200 mg
Dosage adjustment in renal failure:
- start 100 mg QD, increase by 50 mg weekly to maximum dose of 200 mg QD for severe renal impairment
Adverse effects:
- hypertension
- tachycardia
- mania or hypomania
- somnolence
- fatigue
- nausea/vomiting
- insomnia
- irritability
* boxed warning
- potential for suicidal thoughts 7 behaviors, especially within the first few months of treatment or when the dose is changed [1]
Drug interactions:
- MAO inhibitors
- CYP1A2 substrates
Mechanism of action:
- selective norepinephrine reuptake inhibitor
General
selective norepinephrine reuptake inhibitor (SEL-NARI)
Database Correlations
PUBCHEM correlations
References
- Brooks M
FDA Clears Nonstimulant for ADHD in Kids 6 Years and Up.
Medscape - Apr 05, 2021.
https://www.medscape.com/viewarticle/948727
- Monaco K
FDA OKs New Nonstimulant Option for Adult ADHD/
New selective norepinephrine reuptake inhibitor is no longer just for kids.
MedPage Today May 2, 2022
https://www.medpagetoday.com/psychiatry/adhd-add/98504
- Swift Yasgur B.
Nonstimulants: A Better Option for ADHD?
Medscape. July 21, 2023
https://www.medscape.com/viewarticle/994659
- Price MZ, Price RL
Extended-Release Viloxazine Compared with Atomoxetine for Attention Deficit
Hyperactivity Disorder.
CNS Drugs. 2023. 37:655-660
PMID: 37430151
https://link.springer.com/article/10.1007/s40263-023-01023-6
- Qelbree HIGHLIGHTS OF PRESCRIBING INFORMATION
https://www.supernus.com/sites/default/files/Qelbree-Prescribing-Info.pdf